Patients’ perspectives of pharma – a new global survey 2nd edition
In the attachment above, please find: Introduction; Contents of both parts of the report; and Profiling list of patient groups that wish to be named as participants.
Patients’ perspectives of pharma – a new global survey, 2nd edition
Patient View would like to draw your attention to a new two-part report which is available for purchase. If you are interested in purchasing this report, please email Louise Oatham at email@example.com. (Please note that the report is delivered upon receipt of funds.)
About the respondents: 665 patient groups; differing specialties; 47 countries.
About the analyses: Five regions of the world —Australasia; Western Europe; Eastern Europe; North America; and Latin America; and across six medical specialities —Common cancers; Rare cancers; Diabetes; HIV/AIDS; Mental health; and Neurological conditions. —2009 versus 2008.
Contents: PART 1. Pharma’s performance in its relationships with patient groups and with patients. PART 2. Patient groups’ views of corporate strategies, plus the performance of the top-15 pharma companies. —Quality of pharma company relationships with patient groups in 2009 —Views on pharma performance in 2009, according to seven patient group-oriented indicators (innovating to meet patients’ needs; providing information to patient groups; creating relationships with patient groups; managing adverse news about products; being transparent about relationships with patient groups; being trustworthy; and managing conflicts of interest). —Pharma’s record in 2009 on various activities (innovation; disease-awareness campaigns; pricing policies/getting products reimbursed; marketing to doctors; ensuring product safety; truthfulness/accuracy when communicating to patients). —Pharma company strategies to improve relationships with patient groups (consulting and communicating with partner patient groups; supporting patient group operational activities; supporting patient group campaigning activities). —Corporate strategies to help poorer patients during the 2009 global recession. —The performance of the top-15 pharma companies (according to trustworthiness; ability to handle relationships with patient groups; supplying patients with information; understanding patients’ needs). —Wish list for 2010.